
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Managing chronic daily headaches : How to help teens get their lives back Puzzler : Toddler suffers from emesis and weight loss Dermcase : Boy breaks out in body rash Engaging the depressed adolescent






